US-based biotech company Tiziana Life Sciences (Nasdaq: TLSA) today announced the appointment of Ivor Elrifi as Chief Executive Officer (CEO), effective immediately.
“We are delighted to welcome Ivor Elrifi as the new CEO of Tiziana Life Sciences,” said Gabriele Cerrone, Founder and Chairman of the Board of Tiziana, adding, “Ivor has an invaluable track record of creating significant value for biotech and pharmaceutical companies with his strategic vision in building intellectual property portfolios and translating the IP into transformative business development agreements and M&A transactions. Tiziana looks forward to creating further value with Ivor as we progress with our human clinical trials.”
Tiziana says the company is currently focused on advancing intranasal foralumab through clinical trials for non-active secondary progressive multiple sclerosis (na-SPMS), Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). Under Mr. Elrifi’s leadership, the company aims to accelerate these programs and capitalize on opportunities to address significant unmet medical needs.
This article is available to registered users. To continue reading, please register for free. A free trial gives you one week’s access to exclusive features, interviews, summaries and commentary from the brightest minds in pharma and biotech. If you are already a registered user, please log in. If your trial has expired, you can log in here.
Log in to your account
Try before you buy
Free
7 days trial access
Free trial
- All the latest news that makes a difference in the pharmaceutical and biotech industry
- Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life sciences reporters.
- Get the daily news newsletter “The Pharma Letter” free forever.
Become a subscriber
820 €
Or £77 per month
Subscribe now
- Unlimited access to industry-leading news, commentary and analysis from the pharmaceutical and biotechnology sectors.
- News on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulatory, patents and legal, executive appointments, business strategy and financial results.
- Daily summary of the most important events in the pharmaceutical and biotechnology industry.
- Monthly detailed briefings on board appointments and M&A news.
- Choose between a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable service for the life sciences, providing a daily update on performance personnel and products. It is one of the most important pieces of information that keeps me informed
Chairman, Sanofi Aventis UK
